In the first of these, pre-treatment metastatic melanoma biopsies were used for whole-exome sequencing (WES) and RNA-sequencing to identify a sensitivity signature for anti-PD-1 therapy (pembrolizumab or nivolumab). This evidence concerns the gene PDCD1 and metastatic melanoma.